US 12,077,812 B2
Compositions and methods useful in detecting and diagnosing multiple sclerosis
Douglas Feinstein, Chicago, IL (US); and Anne Boullerne, Chicago, IL (US)
Assigned to The United States Government As Represented By The Department Of Veterans Affairs, Washington, DC (US); and The Board Of Trustees Of The University Of Illinois, Urbana, IL (US)
Filed by The United States Government As Represented By The Department of Veterans Affairs, Washington, DC (US); and THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US)
Filed on Apr. 7, 2022, as Appl. No. 17/715,187.
Claims priority of provisional application 63/171,789, filed on Apr. 7, 2021.
Prior Publication US 2022/0333159 A1, Oct. 20, 2022
Int. Cl. C12Q 1/686 (2018.01)
CPC C12Q 1/686 (2013.01) [G01N 2800/285 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method of diagnosing and treating multiple sclerosis (MS) in a subject, the method comprising:
a) obtaining a saliva sample from the subject;
b) detecting in the saliva sample an increased abundance of a Gemella, a Staphylococcus, and a Streptococcus genus of bacteria and a decreased abundance of a Haemophilus, a Campylobacter, and a Prevotella_2 genus of bacteria relative to that of a saliva sample obtained from a control subject, thereby diagnosing MS in the subject; and
c) administering to the subject diagnosed with MS administering a disease-modifying therapy, wherein the disease-modifying therapy is interferon beta-1a, interferon beta-1b, glatiramer acetate, ofatumumab, peginterferon beta-1a, teriflunomide, monomethyl fumarate, dimethyl fumarate, fingolimod, cladribine, siponimod, diroximel fumarate, ozanimod, alemtuzumab, mitoxantrone, ocrelizumab or natalizumab.